Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …
Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis
D Meng, M Yuan, X Li, L Chen, J Yang, X Zhao, W Ma… - Lung cancer, 2013 - Elsevier
K-RAS gene mutations have been found in 20–30% of non-small cell lung cancer and occur
most commonly in adenocarcinoma, however, there was no definitive conclusion about the …
most commonly in adenocarcinoma, however, there was no definitive conclusion about the …
The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
C Boch, J Kollmeier, A Roth, S Stephan-Falkenau… - BMJ open, 2013 - bmjopen.bmj.com
Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck
CM Lewis, BS Glisson, L Feng, F Wan, X Tang… - Clinical Cancer …, 2012 - AACR
Purpose: To determine the disease control rate and toxicity of treating patients with
aggressive cutaneous squamous cell carcinoma (CSCC) with neoadjuvant gefitinib …
aggressive cutaneous squamous cell carcinoma (CSCC) with neoadjuvant gefitinib …
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
A Matikas, D Mistriotis, V Georgoulias… - Critical reviews in …, 2017 - Elsevier
Lung cancer remains the leading cause of cancer-related deaths in both men and women.
However, the discovery of several oncogenic driver mutations and the development of …
However, the discovery of several oncogenic driver mutations and the development of …
[HTML][HTML] KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
W Pan, Y Yang, H Zhu, Y Zhang, R Zhou, X Sun - Oncotarget, 2016 - ncbi.nlm.nih.gov
Mutation of oncogene KRAS is common in non-small cell lung cancer (NSCLC), however, its
clinical significance is still controversial. Independent studies evaluating its prognostic and …
clinical significance is still controversial. Independent studies evaluating its prognostic and …
[HTML][HTML] Clinical outcome of ALK-positive non–small cell lung cancer (NSCLC) patients with De Novo EGFR or KRAS co-mutations receiving tyrosine kinase inhibitors …
S Schmid, O Gautschi, S Rothschild, M Mark… - Journal of Thoracic …, 2017 - Elsevier
Introduction NSCLC with de novo anaplastic lymphoma receptor tyrosine kinase gene (ALK)
rearrangements and EGFR or KRAS mutations co-occur very rarely. Outcomes with tyrosine …
rearrangements and EGFR or KRAS mutations co-occur very rarely. Outcomes with tyrosine …
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
B Ricciuti, GC Leonardi, G Metro… - Expert Review of …, 2016 - Taylor & Francis
Lung cancer is the leading cause of cancer deaths worldwide, with non–small cell lung
cancer (NSCLC) accounting for 80% of all lung cancers. Kirsten rat sarcoma viral oncogene …
cancer (NSCLC) accounting for 80% of all lung cancers. Kirsten rat sarcoma viral oncogene …
KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy
J Guan, W Zhong, S An, J Yang, J Su, Z Chen… - Annals of surgical …, 2013 - Springer
Background The prognostic and predictive value of KRAS mutations in patients with lung
cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient …
cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient …
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non …
O Fiala, M Pesek, J Finek, L Benesova, B Belsanova… - Cancer genetics, 2013 - Elsevier
The role of KRAS mutations in molecular targeted therapy by epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) in non–small cell lung cancer (NSCLC) has …
receptor tyrosine kinase inhibitors (EGFR-TKIs) in non–small cell lung cancer (NSCLC) has …